NEW YORK, Dec. 13, 2016 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, announces the addition to its advisory board of Dr. Ilya Reznik, a Board-certified specialist in Adult Forensic & Clinical Neuro Psychiatry at MaReNa Diagnostic and Consulting Center in Israel and a clinical practitioner utilizing medical cannabis in patient treatment for over ten years.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/72fab073-8871-46cb-a500-08d8e135b8cd
“We are very pleased and honored to have Dr. Reznik join our Advisory Board,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM® Biotech. “Dr. Reznik is a top psychiatry specialist and has extensive clinical experience treating patients with medical cannabis. Since we are contemplating the treatment of drug related and early psychosis, it is very important to enlist a psychiatry specialist on our team. Dr. Reznik is among the best in the world.”
“The highly diverse backgrounds of our distinguished advisory board members, from biopharmaceutical and strategic financing to health and wellness, is a reflection of their unified vision in helping AXIM advance cannabinoid-based research and product development.”
Dr. Reznik has documented contributions to the field of neuropsychiatric research, such as publications in peer-reviewed journals and other innovative activities. He has published original research papers (including controlled trials), reviews and case reports in leading peer-reviewed journals in fields of clinical psychiatry and neuropsychopharmacology.
During the last seven years, Dr. Reznik coordinated the activity of Israel National Forum/Association for Medical Cannabis Research & Treatment. He is an Associate Member of The Canadian Consortium for the Investigation of Cannabinoids (CCIC), Member of International Cannabinoid Research Society (ICRS). In 2013, he was elected to the Board of Directors of the International Association for Cannabinoid Medicines (IACM) and promotes educational and international activities within IACM.
AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, visit www.AXIMBiotech.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
Public Relations Contact: Andrew Hard Chief Executive Officer CMW Media P. 888-829-0070 email@example.com www.cmwmedia.com Corporate Contact Info: North American Address: 18 East 50th Street, 5 Floor New York, NY 10022 +1 844 294 6246 European Address: Boelewerf 32, Unit 3 2987 VD Ridderkerk, The Netherlands +31 10 8209 227
Source:AXIM Biotechnologies, Inc